Multispecific antibodies have emerged as versatile therapeutic agents, and therefore, approaches to optimize and streamline their design and assembly are needed. Here we report on the modular and programmable assembly of IgG antibodies, F(ab) and scFv fragments on DNA origami nanocarriers. We screened 105 distinct quadruplet antibody variants in vitro for the ability to activate T cells in the presence of target cells. T-cell engagers were identified, which in vitro showed the specific and efficient T-cell-mediated lysis of five distinct target cell lines. We used these T-cell engagers to target and lyse tumour cells in vivo in a xenograft mouse tumour model. Our approach enables the rapid generation, screening and testing of bi- and multispecific antibodies to facilitate preclinical pharmaceutical development from in vitro discovery to in vivo proof of concept.
Institut(e)Unit for Clinical Pharmacology (KKG-EKLiP)
FörderungenDeutsche Forschungsgemeinschaft (DFG) Medical Valley Award GO-Bio initial award (Federal Ministry of Education and Research (BMBF) of Germany) a ForTra gGmbH fuer Forschungstransfer der Else Kroener-Fresenius Stiftung Max Planck School Matter to Life - Federal Ministry of Education and Research (BMBF) of Germany Max Planck Society Bavarian Academy of Science international doctoral program the Foerderprogramm fuer Forschung und Lehre der Medizinischen Fakultaet der LMU DFG Elite Network of Bavaria Melanoma Research Alliance Horizon 2020 programme of the European Union Else Kroener-Fresenius-Stiftung German Cancer Aid Ernst Jung Stiftung European Research Council Consolidator Grant Institutional Strategy LMUexcellent of LMU Munich Bundesministerium fuer Bildung und Forschung European Research Council Fritz-Bender Foundation Deutsche Jose Carreras Leukaemie Stiftung Hector Foundation